• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.

作者信息

Whitley Richard

机构信息

From the University of Alabama at Birmingham, Birmingham.

出版信息

N Engl J Med. 2022 Feb 10;386(6):592-593. doi: 10.1056/NEJMe2117814. Epub 2021 Dec 16.

DOI:10.1056/NEJMe2117814
PMID:34914869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8693684/
Abstract
摘要

相似文献

1
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.莫努匹拉韦——迈向新冠口服生物可利用疗法的一步。
N Engl J Med. 2022 Feb 10;386(6):592-593. doi: 10.1056/NEJMe2117814. Epub 2021 Dec 16.
2
Molnupiravir and Its Antiviral Activity Against COVID-19.莫努匹韦及其抗 COVID-19 的抗病毒活性。
Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022.
3
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.解析莫努匹韦诱导 SARS-CoV-2 突变。
J Biol Chem. 2021 Jul;297(1):100867. doi: 10.1016/j.jbc.2021.100867. Epub 2021 Jun 9.
4
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination.严重急性呼吸综合征冠状病毒2型奥密克戎变种对莫努匹拉韦、奈玛特韦及二者联用高度敏感。
Cell Res. 2022 Mar;32(3):322-324. doi: 10.1038/s41422-022-00618-w. Epub 2022 Jan 20.
5
Use of molnupiravir: A Danish nationwide drug utilization study.莫努匹拉韦的使用：一项丹麦全国性药物利用研究。
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5700. doi: 10.1002/pds.5700. Epub 2023 Sep 24.
6
Molnupiravir: A new candidate for COVID-19 treatment.莫努匹韦：COVID-19 治疗的新候选药物。
Pharmacol Res Perspect. 2022 Feb;10(1):e00909. doi: 10.1002/prp2.909.
7
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.基于 N4-羟胞苷的新型缀合物，其体外抗 SARS-CoV-2 和其他人类冠状病毒的抗病毒效力比 EIDD-2801 更强。
Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28.
8
A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe.莫努匹拉韦抗新型冠状病毒2复制的新模型：累积RNA突变以引发错误灾难。
Signal Transduct Target Ther. 2021 Dec 2;6(1):410. doi: 10.1038/s41392-021-00837-4.
9
An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.一种工程化的胞嘧啶脱氨酶用于生物催化生产新冠病毒抗病毒药物 Molnupiravir 的关键中间体。
J Am Chem Soc. 2022 Mar 9;144(9):3761-3765. doi: 10.1021/jacs.1c11048. Epub 2022 Feb 28.
10
Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients?莫努匹拉韦会成为我们拯救新冠门诊患者努力中的一个改变游戏规则的因素吗？
Pol Arch Intern Med. 2022 Jan 28;132(1). doi: 10.20452/pamw.16183. Epub 2022 Jan 3.

引用本文的文献

1
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case-Control Study (SAVALO Study).莫努匹拉韦降低新冠病毒感染患者严重结局风险的疗效：一项真实世界完全匹配病例对照研究（SAVALO研究）
Microorganisms. 2025 Mar 15;13(3):669. doi: 10.3390/microorganisms13030669.
2
Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.中国湖南省北部新冠肺炎血液透析患者死亡的危险因素
BMC Nephrol. 2025 Jan 16;26(1):26. doi: 10.1186/s12882-025-03946-2.
3
Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea.韩国全国靶向试验模拟评估口服抗新冠病毒药物的临床疗效。
J Korean Med Sci. 2024 Nov 4;39(42):e272. doi: 10.3346/jkms.2024.39.e272.
4
BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.BPR3P0128 是一种非核苷类 RNA 依赖性 RNA 聚合酶抑制剂，能够抑制 SARS-CoV-2 关切变异株，并与瑞德西韦联合具有协同抗病毒活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0095623. doi: 10.1128/aac.00956-23. Epub 2024 Mar 6.
5
Plasma Sphingomyelin Disturbances: Unveiling Its Dual Role as a Crucial Immunopathological Factor and a Severity Prognostic Biomarker in COVID-19.血浆神经鞘磷脂紊乱：揭示其在 COVID-19 中作为关键免疫病理因子和严重程度预后生物标志物的双重作用。
Cells. 2023 Jul 26;12(15):1938. doi: 10.3390/cells12151938.
6
Codivir suppresses SARS-Cov-2 viral replication and stabilizes clinical outcome: In vitro and Phase I clinical trial results.可迪维抑制新型冠状病毒复制并稳定临床结果：体外及I期临床试验结果
Discoveries (Craiova). 2022 Dec 31;10(4):e158. doi: 10.15190/d.2022.17. eCollection 2022 Oct-Dec.
7
OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2.寡聚结合物：生物工程可溶性淀粉样纳米颗粒，用于结合和中和 SARS-CoV-2。
ACS Appl Mater Interfaces. 2023 Mar 8;15(9):11444-11457. doi: 10.1021/acsami.2c18305. Epub 2023 Feb 22.
8
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.莫努匹拉韦：一种针对新冠病毒变异株的多功能前药。
Metabolites. 2023 Feb 20;13(2):309. doi: 10.3390/metabo13020309.
9
The development of COVID-19 treatment.COVID-19 治疗的发展。
Front Immunol. 2023 Jan 26;14:1125246. doi: 10.3389/fimmu.2023.1125246. eCollection 2023.
10
Evaluation of an automated CRISPR-based diagnostic tool for rapid detection of COVID-19.一种基于CRISPR的自动化诊断工具用于快速检测新型冠状病毒肺炎的评估
Heliyon. 2023 Feb;9(2):e13190. doi: 10.1016/j.heliyon.2023.e13190. Epub 2023 Jan 23.

本文引用的文献

1
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.Molnupiravir 治疗非住院成人 COVID-19 的 2/3 期试验。
NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/EVIDoa2100043. Epub 2021 Dec 16.
2
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.莫努匹拉韦或安慰剂用于新冠肺炎住院患者的随机试验
NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16.
3
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
4
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.开发一种直接作用的、口服有效的抗病毒药物以应对大流行：莫努匹韦作为 COVID-19 潜在治疗药物的发展历程。
Curr Opin Virol. 2021 Oct;50:17-22. doi: 10.1016/j.coviro.2021.06.003. Epub 2021 Jun 18.
5
Letter to the Editor in Response to Zhou et al.致编辑的信：回应周等人的文章
J Infect Dis. 2021 Oct 28;224(8):1442-1443. doi: 10.1093/infdis/jiab362.
6
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.β-d-N4-羟基胞苷通过致命诱变抑制 SARS-CoV-2，但对哺乳动物细胞也具有诱变作用。
J Infect Dis. 2021 Aug 2;224(3):415-419. doi: 10.1093/infdis/jiab247.
7
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.瑞德西韦（EIDD-2801）能有效治疗和预防 SARS-CoV-2 感染。
Nature. 2021 Mar;591(7850):451-457. doi: 10.1038/s41586-021-03312-w. Epub 2021 Feb 9.
8
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.治疗性给予核苷类似物 MK-4482/EIDD-2801 可阻断雪貂体内的 SARS-CoV-2 传播。
Nat Microbiol. 2021 Jan;6(1):11-18. doi: 10.1038/s41564-020-00835-2. Epub 2020 Dec 3.
9
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
10
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.奥司他韦治疗成人流感：随机对照试验的荟萃分析。
Lancet. 2015 May 2;385(9979):1729-1737. doi: 10.1016/S0140-6736(14)62449-1. Epub 2015 Jan 30.